Treatment of multiple myeloma with selinexor: a review

Treatment of multiple myeloma with selinexor: a review

Over the last 20 years, breakthroughs in accessible therapies for the treatment of multiple myeloma (MM) have been made. Nevertheless, patients with MM resistant to immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies have a very poor outcome. Therefore, it is necessary...

Full description

Bibliographic Details
Main Authors:	Qianlei Huang, Ranran Zhao, Lu Xu, Xinbao Hao, Shi Tao
Format:	Article
Language:	English
Published:	SAGE Publishing 2024-01-01
Series:	Therapeutic Advances in Hematology
Online Access:	https://doi.org/10.1177/20406207231219442

Similar Items

Selinexor in relapsed/refractory multiple myeloma
by: Joshua Richter, et al.
Published: (2020-06-01)

Selinexor: Targeting a novel pathway in multiple myeloma
by: Clifton C. Mo, et al.
Published: (2023-08-01)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
by: Cristina Gasparetto, et al.
Published: (2021-02-01)

Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease
by: Junjing Yin, et al.
Published: (2024-11-01)

Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis
by: Xinyuan Gu, et al.
Published: (2023-12-01)

US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma
by: Bassali J, et al.
Published: (2020-06-01)

PB2096: SELINEXOR COMBINED REGIMEN FOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE(EMD)
by: Yuping Zhong, et al.
Published: (2023-08-01)

Identification and evaluation of a six-lncRNA prognostic signature for multiple myeloma
by: Lu Xu, et al.
Published: (2024-06-01)

Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors
by: Adam F. Binder, et al.
Published: (2023-10-01)

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
by: Nina Nguyen, et al.
Published: (2022-10-01)

Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor
by: Lucio N. Gordan, et al.
Published: (2024-01-01)

Selinexor in combination with dexamethasone with or without bortezomib in heavily pretreated multiple myeloma: A case series
by: Nini Aung, et al.
Published: (2024-10-01)

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment
by: Muhamed Baljevic, et al.
Published: (2022-11-01)

Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
by: Michael Dolph, et al.
Published: (2021-08-01)

PB2138: ORAL REGIMEN SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): SAFETY ASSESSMENT AND OPTIMIZATION
by: Juan Du, et al.
Published: (2023-08-01)

P920: EFFECTIVENESS AND SAFETY OF SELINEXOR-BASED REGIMEN IN THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A MULTICENTER REAL-WORLD STUDY FROM CHINA
by: L. Kuang, et al.
Published: (2022-06-01)

P917: SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: UPDATED RESULTS OF BOSTON TRIAL BY PRIOR THERAPIES
by: Maria-Victoria Mateos, et al.
Published: (2023-08-01)

Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
by: Darrell White, et al.
Published: (2024-05-01)

Targeting deubiquitinase USP7-mediated stabilization of XPO1 contributes to the anti-myeloma effects of selinexor
by: Junying Wang, et al.
Published: (2025-01-01)

Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study
by: Verónica González-Calle, et al.
Published: (2024-02-01)

Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma
by: Paul G. Richardson, et al.
Published: (2021-02-01)

P878: SELINEXOR IN COMBINATION WITH DARATUMUMAB-BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF RELAPSE OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF THE PHASE 2, MULTICENTER GEM-SELIBORDARA STUDY
by: Veronica Gonzalez-Calle, et al.
Published: (2023-08-01)

P888: MATCHED-ADJUSTED INDIRECT COMPARISON OF TALQUETAMAB VS SELINEXOR-DEXAMETHASONE AND VS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: Ajai Chari, et al.
Published: (2023-08-01)

PB2106: REAL-WORLD SAFETY AND EFFECTIVENESS OF SELINEXOR-BASED REGIMENS IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA AND DIALYSIS-DEPENDENT RENAL IMPAIRMENT
by: James Niblock, et al.
Published: (2023-08-01)

P974: INTERIM ANALYSIS OF THE LAUNCH STUDY-A MULTICENTER, OPEN-LABEL STUDY OF SELINEXOR, DEXAMETHASONE PLUS CHEMOTHERAPY DRUGS IN RELAPSED/ REFRACTORY MULTIPLE MYELOMA
by: Chunyan Sun, et al.
Published: (2023-08-01)

PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON
by: L. Rosinol, et al.
Published: (2022-06-01)

P886: EFFICACY, SURVIVAL AND SAFETY OF SELINEXOR, BORTEZOMIB AND DEXAMETHASONE (SVD) IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SUBGROUP DATA FROM THE BOSTON TRIAL
by: Maria-Victoria Mateos, et al.
Published: (2023-08-01)

P976: REAL-WORLD OUTCOMES OF PATIENTS WITH PENTA-EXPOSED MULTIPLE MYELOMA WHO WERE TREATED WITH SELINEXOR AND DEXAMETHASONE: KOREAN MULTICENTER RETROSPECTIVE ANALYSIS
by: Jun Ho Yi, et al.
Published: (2023-08-01)

Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study)
by: Hamid Ehsan, et al.
Published: (2024-03-01)

P982: EFFICACY AND SAFETY OF 40 MG VS 60 MG OF ONCE WEEKLY SELINEXOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
by: Darrell White, et al.
Published: (2023-08-01)

Beyond oncology: Selinexor’s journey into anti-inflammatory treatment and long-term management
by: Dan Li, et al.
Published: (2024-05-01)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
by: Sonam Mittal, et al.
Published: (2023-09-01)

Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
by: Lugui Qiu, et al.
Published: (2022-04-01)

Case report: Safety and efficacy of synergistic treatment using selinexor and azacitidine in patients with atypical chronic myeloid leukemia with resistance to decitabine
by: Lu Liu, et al.
Published: (2024-02-01)

MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma
by: Andrew Hall, et al.
Published: (2022-10-01)

Review of the Expert Council “Multiple myeloma: the era of monoclonal antibodies in the treatment of patients with multiple myeloma”
by: M. I. Akhmedov, et al.
Published: (2024-01-01)

Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia
by: Mariarita Spampinato, et al.
Published: (2024-07-01)

A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma
by: Mohamed A. Gouda, et al.
Published: (2024-11-01)

Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the GEMS‐001 clinical trial
by: Alberto Hernando‐Calvo, et al.
Published: (2023-10-01)

Immunotherapy for the treatment of multiple myeloma
by: Leora S. Boussi, et al.
Published: (2022-10-01)